151 related articles for article (PubMed ID: 12134365)
1. Positron emission tomography for evaluation of colorectal carcinoma.
Vitola J; Delbeke D
Semin Roentgenol; 2002 Apr; 37(2):118-28. PubMed ID: 12134365
[TBL] [Abstract][Full Text] [Related]
2. PET and PET-CT for evaluation of colorectal carcinoma.
Delbeke D; Martin WH
Semin Nucl Med; 2004 Jul; 34(3):209-23. PubMed ID: 15202102
[TBL] [Abstract][Full Text] [Related]
3. FDG PET and PET/CT for colorectal cancer.
Delbeke D; Martin WH
Methods Mol Biol; 2011; 727():77-103. PubMed ID: 21331930
[TBL] [Abstract][Full Text] [Related]
4. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
Metser U; You J; McSweeney S; Freeman M; Hendler A
AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
6. [Importance of FDG-PET/computed tomography in colorectal cancer].
Kleiner S; Weber W
Radiologe; 2019 Sep; 59(9):812-819. PubMed ID: 31428810
[TBL] [Abstract][Full Text] [Related]
7. Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET).
Schmid RA; Hautmann H; Poellinger B; Kellner W; Moisseev A; Brinkbaeumer K; Weiss M; Hahn K; Dresel S
Nucl Med Commun; 2003 Jan; 24(1):37-45. PubMed ID: 12501018
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
10. Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma.
Kato H; Miyazaki T; Nakajima M; Fukuchi M; Manda R; Kuwano H
Br J Surg; 2004 Aug; 91(8):1004-9. PubMed ID: 15286962
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography in colorectal cancer.
Flamen P
Best Pract Res Clin Gastroenterol; 2002 Apr; 16(2):237-51. PubMed ID: 11969236
[TBL] [Abstract][Full Text] [Related]
12. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
Odalovic S; Stojiljkovic M; Sobic-Saranovic D; Pandurevic S; Brajkovic L; Milosevic I; Grozdic-Milojevic I; Artiko V
Neoplasma; 2017; 64(6):954-961. PubMed ID: 28895416
[TBL] [Abstract][Full Text] [Related]
13. FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma.
Willkomm P; Bender H; Bangard M; Decker P; Grünwald F; Biersack HJ
J Nucl Med; 2000 Oct; 41(10):1657-63. PubMed ID: 11037995
[TBL] [Abstract][Full Text] [Related]
14. [Positron emission tomography for the preoperative staging of esophageal carcinoma].
Junginger T; Kneist W; Schreckenberger M; Menzel C; Oberholzer K; Bartenstein P
Dtsch Med Wochenschr; 2002 Sep; 127(38):1935-41. PubMed ID: 12239652
[TBL] [Abstract][Full Text] [Related]
15. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC
Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
[TBL] [Abstract][Full Text] [Related]
16. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study.
Strasberg SM; Dehdashti F; Siegel BA; Drebin JA; Linehan D
Ann Surg; 2001 Mar; 233(3):293-9. PubMed ID: 11224615
[TBL] [Abstract][Full Text] [Related]
17. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer.
Valk PE; Abella-Columna E; Haseman MK; Pounds TR; Tesar RD; Myers RW; Greiss HB; Hofer GA
Arch Surg; 1999 May; 134(5):503-11; discussion 511-3. PubMed ID: 10323422
[TBL] [Abstract][Full Text] [Related]
18. Selection of patients for resection of hepatic metastases: improved detection of extrahepatic disease with FDG pet.
Zealley IA; Skehan SJ; Rawlinson J; Coates G; Nahmias C; Somers S
Radiographics; 2001 Oct; 21 Spec No():S55-69. PubMed ID: 11598248
[TBL] [Abstract][Full Text] [Related]
19. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography.
Ogunbiyi OA; Flanagan FL; Dehdashti F; Siegel BA; Trask DD; Birnbaum EH; Fleshman JW; Read TE; Philpott GW; Kodner IJ
Ann Surg Oncol; 1997 Dec; 4(8):613-20. PubMed ID: 9416407
[TBL] [Abstract][Full Text] [Related]
20. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
Laurens ST; Oyen WJ
PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]